Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613320 | 0.89 | MEN1 (0.56) | KDRALDH1A1MAPTNPC1KDM4D | |
| SCHEMBL9613301 | 0.86 | KDM4D (0.67) | ALDH1A1MAPTSMN1; SMN2GAALMNA | |
| SCHEMBL9613360 | 0.85 | RAB9A (0.60) | ALDH1A1MAPTSMN1; SMN2GAANPC1 | |
| SCHEMBL9613392 | 0.84 | KDR (0.43) | KDRALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL9613314 | 0.83 | MAPT (0.53) | KDRALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL9613294 | 0.82 | KDM4D (0.73) | ALDH1A1MAPTHTTNPSR1TDP1 | |
| SCHEMBL12111585 | 0.79 | KMT2A (0.67) | ALDH1A1MAPTSMN1; SMN2GAAHTT | |
| SCHEMBL12111638 | 0.79 | KMT2A (0.67) | ALDH1A1MAPTSMN1; SMN2GAAHTT | |
| SCHEMBL28037045 | 0.79 | KMT2A (0.67) | ALDH1A1MAPTSMN1; SMN2GAAHTT | |
| SCHEMBL28037442 | 0.79 | KMT2A (0.67) | ALDH1A1MAPTSMN1; SMN2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353094-B2 | Substituted quinoxalines as kinase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-10-01 | — | — | US | disclosed |
| US-8993758-B2 | Substituted quinoxalines and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012071414-A2 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDR 2125/4885ALDH1A1 4080/4885MAPT 3965/4885 |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDR 2125/4885ALDH1A1 4080/4885MAPT 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.